<DOC>
	<DOCNO>NCT03030599</DOCNO>
	<brief_summary>This double-blind , placebo-controlled , randomized-withdrawal , multicenter study efficacy safety JZP-258 .</brief_summary>
	<brief_title>A Study Efficacy Safety JZP-258 Subjects With Narcolepsy With Cataplexy</brief_title>
	<detailed_description>Subjects transition JZP-258 base treatment status study entry . All subject begin JZP-258 treatment begin period continue Week 12 . They treat JZP-258 alone final two week 12-week period . Once JZP-258 dose optimize per Investigator 's judgment , subject may enter 2-week Stable-Dose Period dose . Subjects eligible enter Double-Blind Randomized-Withdrawal Period dose JZP-258 remains unchanged Stable-Dose Period , judgment Investigator , clinically significant worsen narcolepsy symptom clinically significant adverse event due JZP-258 treatment occur . Subjects return Safety Follow-up visit 2 week Double-Blind Randomized-Withdrawal Period .</detailed_description>
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Cataplexy</mesh_term>
	<criteria>1 . Male female subject 18 70 year age , inclusive . 2 . Have primary diagnosis narcolepsy cataplexy meet ICSD3 criterion DSM5 criterion , currently untreated treat without anticataplectics . 3 . If applicable , treat stimulant alert agent unchanged dos least 2 month prior dose treat stimulant alert agent . 4 . Willing able comply study design schedule requirement . 5 . Willing able provide write informed consent . 1 . Narcolepsy secondary another medical condition ( e.g. , CNS injury lesion ) 2 . History presence unstable clinically significant medical condition , behavioral psychiatric disorder ( include active suicidal ideation ) , history presence another neurological disorder surgical history might affect subject 's safety and/or interfere conduct study opinion Investigator . 3 . Treatment central nervous system sedate agent , include limited benzodiazepine , nonbenzodiazepine anxiolytics/ hypnotics/sedatives , neuroleptic , opioids , barbiturate , phenytoin , ethosuximide , MCT inhibitor , e.g . diclofenac , valproate , ibuprofen , within 2 week prior enrollment ( discontinuation purpose study enrollment permit consider safe Investigator approve Medical Monitor ) . 4 . Treatment antidepressant cataplexy , withdrawal antidepressant crosstitration JZP258 might unsafe due prior history depression . 5 . Unsafe subject receive placebo treatment 2 week , opinion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>